<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168060">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769599</url>
  </required_header>
  <id_info>
    <org_study_id>0108-12-ZIV</org_study_id>
    <nct_id>NCT01769599</nct_id>
  </id_info>
  <brief_title>Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      there is no yet agreement about the best way to treat Diabetic Macular Edema (DME) the two
      options up to day are using Grid laser treatment Vs. Avastin injections or a combination of
      both in this study we want to compare the two attitudes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Macular thickness</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>by measuring the retinal thickness and comparing in both aproaches. and see if there is any difference.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetus Mellitus</condition>
  <arm_group>
    <arm_group_label>Grid Treatment</arm_group_label>
    <description>30 patients that were treated with laser grid treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin Treatment</arm_group_label>
    <description>patients that were treated with Avastin injections</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic people that suffer from macular edema
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with macular edema

          -  age 30 to 80 Yrs. old

          -  no previous ocular treatment

          -  patiens with macular edema that was shown by OCT or FA

          -  patients with at least 6 months follow-up after the last treatment

        Exclusion Criteria:

          -  patients with other ocular disease (such as glaucoma etc.)

          -  patients with previous ocular surgery

          -  patiens with eye trauma

          -  patiens with macular edema not from DM
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joseph Pikkel, M.D</last_name>
    <phone>+972-50-4348206</phone>
    <email>pikel.y@ziv.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otzem Chassid, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Pikkel, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 14, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziv Hospital</investigator_affiliation>
    <investigator_full_name>yehudit.hackmon</investigator_full_name>
    <investigator_title>Reaserch coordinator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
